NCT06573593Recruiting
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- No phase declared
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Participants (registry)
- 150
- Start
- July 2024
- Primary completion
- December 2026 (planned)
- Study completion
- December 2026 (planned)
- Last registry update
- August 2024
- Countries
- China
Conditions studied: Alopecia Areata, Janus Kinase Inhibitors
Interventions: Tofacitinib, Baricitinib, Ruxolitinib, Upadacitinib, Abrocitinib, Ritlecitinib
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.